
CLAIMS

1. Use of a S1P receptor modulator in the manufacture of a medicament for treating hematological malignancies by preventing chronic graft-versus-host-disease (cGVHD) or delaying relapse or increasing relapse-free survival, in a subject undergoing allogeneic hematopoietic stem cell transplant (HSCT), wherein said S1P receptor modulator, or a pharmaceutically acceptable salt thereof, is to be administered daily for at least 6 months.

2. The use according to claim 1 which has the formula (I) or (II), in particular which is mocravimod, or a pharmaceutically acceptable salt thereof:




wherein

R_2 is H, halogen, trihalomethyl, C_{1-4}alkoxy, C_{1-7}alkyl, phenethyl or benzyloxy;

R_3 is H, halogen, CF_3, OH, C_{1-7}alkyl, C_{1-4}alkoxy, benzyloxy, phenyl or C_{1-4}alkoxymethyl;

each of R_4 and R_5, independently is H or a residue of formula (a)




(a)

wherein each of R_8 and R_9, independently, is H or C_{1-4}alkyl optionally substituted by halogen;

and n is an integer from 1 to 4; and

R_6 is hydrogen, halogen, C_{1-7}alkyl, C_{1-4}alkoxy or trifluoromethyl,



or is a pharmaceutically acceptable salt thereof.

3. Use of the S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof according to claim 1, wherein said hematological malignancy is acute myeloid leukemia (AML).

4. Use of the S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof according to claim 1 to 3, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is to be administered daily for at least 12 months, or more, or until relapse.

5. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-4, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is to be administered daily from a starting day between 1-14 days prior to HSC transplant, preferably 11 days before HSC transplant.

6. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is to be administered at a daily dose of 3mg.

7. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is to be administered at a daily dose of 1mg.

8. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-7, wherein said hematological malignancy is acute myeloid leukemia, said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is to be administered at a daily dose of 1mg or 3 mg for at least 12 months.

9. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-8, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is formulated as a solid dosage form, said solid dosage form comprising:

- mannitol;
- microcrystalline cellulose ;
- sodium starch glycolate;
- magnesium stearate; and
- colloidal silicon dioxide.

10. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-9, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is formulated as a solid dosage form, said solid dosage form comprising:

- mannitol at a content from 48 to 88 mg/unit;
- microcrystalline cellulose at a content from 5 to 45 mg/unit;
- sodium starch glycolate at a content from 1 to 8 mg/unit;
- magnesium stearate at a content from 0.025 to 4 mg/unit; and
- colloidal silicon dioxide at a content from 0.125 to 2 mg/unit.

11. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-10, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is formulated as a solid dosage form, said solid dosage form comprising:

- mannitol at a content from 58 to 78mg/unit;
- microcrystalline cellulose at a content from 15 to 35 mg/unit;
- sodium starch glycolate at a content from 2 to 6 mg/unit;

- magnesium stearate at a content from 0.5 to 2 mg/unit; and
- colloidal silicon dioxide at a content from 0.25 to 1 mg/unit.

12. Use of the S1P receptor modulator in particular mocravimod or a pharmaceutically acceptable salt thereof according to any one of claims 1-10, wherein said S1P receptor modulator, in particular mocravimod or a pharmaceutically acceptable salt thereof, is formulated as a solid dosage form, said solid dosage form comprising:

- mannitol at a content about 68 mg/unit;
- microcrystalline cellulose at a content about 25 mg/unit;
- sodium starch glycolate at a content about 4 mg/unit;
- magnesium stearate at a content at a content about 1 mg/unit; and
- colloidal silicon dioxide at a content about 0.5 mg/unit.